Autologous tumor-immune effusion cocultures enable ex vivo functional profiling of radiotherapy-immunotherapy combinations
A new lab platform lets doctors test how individual patients' tumors respond to combined radiation and immunotherapy, moving toward truly personalized cancer treatment planning.
A novel ex vivo coculture platform using patient-derived tumor and immune cells from malignant effusions enables functional testing of radiotherapy combined with immunotherapy at the individual patient level. This precision medicine tool bridges the gap between preclinical models and clinical response prediction for radio-immunotherapy combinations.
What the study was
- Study design
- Preclinical-translational (ex vivo coculture, human specimens)
- Population
- Cancer patients with malignant effusions (pleural/peritoneal), Medical University of Vienna
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal of Experimental & Clinical Cancer Research
Why it surfaced
Innovative autologous ex vivo profiling approach directly addresses personalized radio-immunotherapy selection; limited by no abstract (title-keyword classification) and no clinical outcome data yet.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.